News

SHAREHOLDER WARNING: Pomerantz legislation agency is investigating claims on behalf of buyers from Regeneron Prescribed drugs Inc. – PRNewswire

shareholder-warning-pomerantz-legislation-agency-is-investigating-claims-on-behalf-of-buyers-from-regeneron-prescribed-drugs-inc-prnewswire

NEW YORK, July 31, 2020 / PRNewswire / – Pomerantz LLP is investigating claims on behalf of investors from Regeneron Pharmaceuticals Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).

The investigation concerns whether Regeneron and some of its officers and / or directors have breached the fiduciary duties of the company and its investors.

If you are a Regeneron shareholder and would like additional information about this investigation, please contact Robert S. Willoughby at the (Email protected) or 888-476-6529, extension 7980.

The Pomerantz company with offices in new York, Chicago, los Angeles, and Paris is recognized as a leader in corporate, securities and antitrust litigation. Founded by the late Abraham L. PomerantzThe Pomerantz company, known as the dean of the class action lawsuit, was a pioneer in the field of class action lawsuits for securities. Today, more than 80 years later, the Pomerantz company continues its tradition and fights for the rights of victims of securities fraud, breaches of trust and misconduct by companies. The company has claimed back several million dollars in damages on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
(Email protected)
888-476-6529 extension 7980

SOURCE Pomerantz LLP

related links

www.pomerantzlaw.com

0 Comments
Share

labsurlab

Reply your comment

Your email address will not be published. Required fields are marked*